7 research outputs found
Kardiovaskularni postizeni u Fabryho nemoci s durazem na endotelialni dysfunkci.
The goal of this project was to assess the degree of endothelial dysfunction in the presence of morphological changes and to evaluate the extent of cardiovascular impairment. Besides mapping of cardiovascular symptoms and assessing the degree of organ involvement, we have evaluated several markers reflecting endothelial function. The evaluation of early stages of the disease by establishing endothelial function markers is difficult and our results in most of them did not give significant findings. The best correlation between cardiovascular impairment and the evaluated levels was found in endothelaemia, endotelin-1 level, levels of orosomucoid and fibrinogen. Cardiovascular involvement is most typically characterized by the concentric left ventricle hypertrophy and its remodelling. Even in the presence of the fact that all symptoms and organ involvements have been extensively studied in this project and had possibility to be detected early there is no casual therapy for these patients available and their prognosis stays serious.Summary in English. Text also in English.Available from STL, Prague, CZ / NTK - National Technical LibrarySIGLECZCzech Republi
Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial
BACKGROUND: Chronic venous disorders (CVD) is estimated to affect 30% to 50% of women and 10% to 30% of men. The most widely prescribed treatment for CVD worldwide is micronized purified flavonoid fraction 500 mg (MPFF). The aim of this clinical trial was to develop a new once daily 1000-mg oral suspension of MPFF
Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
International audienc
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
COVID-19 is also manifested with hypercoagulability, pulmonary
intravascular coagulation, microangiopathy, and venous thromboembolism
(VTE) or arterial thrombosis. Predisposing risk factors to severe
COVID-19 are male sex, underlying cardiovascular disease, or
cardiovascular risk factors including noncontrolled diabetes mellitus or
arterial hypertension, obesity, and advanced age. The VAS-European
Independent Foundation in Angiology/Vascular Medicine draws attention to
patients with vascular disease (VD) and presents an integral strategy
for the management of patients with VD or cardiovascular risk factors
(VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary
health care network for patients with VD-CVR for identification of
patients with VD-CVR in the community and patients' education for
disease symptoms, use of eHealth technology, adherence to the
antithrombotic and vascular regulating treatments, and (2) close medical
follow-up for efficacious control of VD progression and prompt
application of physical and social distancing measures in case of new
epidemic waves. For patients with VD-CVR who receive home treatment for
COVID-19, VAS recommends assessment for (1) disease worsening risk and
prioritized hospitalization of those at high risk and (2) VTE risk
assessment and thromboprophylaxis with rivaroxaban, betrixaban, or
low-molecular-weight heparin (LMWH) for those at high risk. For
hospitalized patients with VD-CVR and COVID-19, VAS recommends (1)
routine thromboprophylaxis with weight-adjusted intermediate doses of
LMWH (unless contraindication); (2) LMWH as the drug of choice over
unfractionated heparin or direct oral anticoagulants for the treatment
of VTE or hypercoagulability; (3) careful evaluation of the risk for
disease worsening and prompt application of targeted antiviral or
convalescence treatments; (4) monitoring of D-dimer for optimization of
the antithrombotic treatment; and (5) evaluation of the risk of VTE
before hospital discharge using the IMPROVE-D-dimer score and prolonged
post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH